Fierce Biotech covered Antidote's funding news and shared how it will make an impact. The article writes:
"Now, with the new funding, which brings the total investment Antidote has received to $26 million, the company plans to enhance its capabilities with such features as precision medicine and electronic health record-matching, as well as to expand its footprint globally. Currently headquartered in New York, the company also has offices in London and Indiana. As part of the Cancer Moonshot project, the company will also match cancer patients with specific mutations to pertinent studies."
Read more on Fierce Biotech.
